Although potent antiplatelet agents and early revascularization have improved the prognosis for patients with acute myocardial infarction (MI), bleeding complications may result in substantial morbidity or mortality. Major bleeding See page 1757 has been identified as an independent risk factor for mortality after acute MI (1, 2) . Previous reports have suggested that major bleeding in patients with acute coronary syndromes treated with an early invasive strategy confers an increased risk for both short-term and mid-term mortality (3) (4) (5) . However, few studies have evaluated the impact of in-hospital major bleeding (IHMB) on longer-term outcomes in these patients.
Accordingly, we sought to evaluate the clinical correlates and impact of IHMB on the 3-year outcomes after primary percutaneous coronary intervention (PCI) for acute MI among randomized participants in the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
Methods
The design of the HORIZONS-AMI trial has been previously described (4) . Endpoints for the current analysis included allcause mortality, the composite endpoint of major adverse clinical events (MACE) (composite of death, reinfarction, target vessel revascularization for ischemia, or stroke), and stent thrombosis (ST, definite, or probable) at 3-year follow-up. Major bleeding was defined as the occurrence of any of the following: intracranial bleeding, intraocular bleeding, retroperitoneal bleeding, access site hemorrhage requiring surgery or radiologic or interventional procedure, hematoma Ն5 cm in diameter at the puncture site, reduction in hemoglobin concentration of Ն4 g/dl without an committee adjudicated all primary endpoints and ST events throughout the 3-year follow-up period.
For the current analysis, we compared the 3-year clinical outcomes in patients with a non-CABG-related major bleeding event as their first in-hospital adverse event after the index procedure with patients who did not have major bleeding during their hospital course. Statistical methods. Categorical variables are presented as percentages and were compared with the chi-square test or Fisher exact test. Continuous variables are presented as medians with interquartile ranges and were compared using Mann-Whitney U test.
Predictors of IHMB were identified with logistic regression analyses. The following variables were entered: age, female sex, body mass index, hypertension, hyperlipidemia, smoking, diabetes, previous MI, previous CABG, previous angina, previous heart failure, baseline thrombocytopenia, baseline anemia, renal insufficiency (defined as estimated glomerular filtration rate Ͻ60 ml/min), use of pre-randomization heparin, antiplatelet medication use in the past 5 days, pharmacologic randomization arm, loading dose of clopidogrel, symptom to balloon time, and culprit lesion in left anterior descending artery.
Rates of clinical endpoints were compared between patients with and without IHMB cumulative to 3 years and within 3 separate time intervals (0 to 30 days, 30 days to 1 year, and 1 to 3 years). The results are displayed using Kaplan-Meier estimates and compared using the log-rank test.
Cox proportional hazards analysis was used to identify independent predictors of 3-year mortality. The multivariate model was built by stepwise variable selection with entry and exit criteria set at the p ϭ 0.1 level, and we selected all relevant variables from previous studies as candidate variables for this model. Variables included in the multivariable model were age, sex, diabetes mellitus, Killip class, baseline anemia, white blood cell count, renal insufficiency, hypertension, hyperlipidemia, previous MI, smoking, pharmacologic randomization arm, loading dose of clopidogrel, culprit lesion in left anterior descending artery, symptom to first balloon time, and final Thrombolysis In Myocardial Infarction flow grade 3. IHMB and in-hospital ST were forced into the outcomes model.
As a secondary analysis, Cox proportional hazards analysis was repeated for in-hospital survivors only. In addition to the same variables used in the previous model, we included prescription of a statin, beta-blocker, or a thienopyridine at discharge as variables in this model. A p value Ͻ0.05 was considered statistically significant.
Results

Patient characteristics.
Primary PCI was performed in 3,345 (92.9%) of 3,602 randomized patients; in-hospital protocol-defined non-CABG-related major bleeding developed in 231 (6.9%). Thirteen cases were excluded because the bleeding events developed after thrombotic complications (reinfarction, n ϭ 1; stroke, n ϭ 1; ischemic target vessel revascularization, n ϭ 2; or ST, n ϭ 9). Table 1 shows the baseline clinical, angiographic, and procedural characteristics of patients. Patients with IHMB were older, more often female, more often had a history of congestive heart failure, had a higher Killip class, and had a lower body mass index. Moreover, they were more likely to have diabetes mellitus, anemia, and renal insufficiency. IHMB occurred less frequently in patients randomized to bivalirudin. Table 2 shows antithrombotic medication use in patients. A 600-mg loading dose of clopidogrel and bivalirudin was administered less frequently, and glycoprotein IIb/IIIa inhibitors were more often used in patients with bleeding. Independent predictors of IHMB are presented in Figure 1 . Medications use at and after discharge. As shown in Table 2 , there were no significant differences in the prescription rate of aspirin between patients with and without IHMB at discharge, 1 month, and 3 years. At 1 year, however, patients with bleeding were less likely to be taking aspirin. There were no significant differences in thienopyridine use between both groups at discharge, 1 year, and 2 years. However, patients with IHMB were more likely to be taking a thienopyridine at 3 years. Patients with IHMB were less likely to receive a beta-blocker and statin at hospital discharge, but were more likely to receive diuretics, digoxin, and antiarrhythmic agents. Major bleeding and clinical outcomes. Kaplan-Meier estimates of the incidence of MACE and their individual components at 3 years and between 0 to 30 days, 30 days to 1 year, and 1 to 3 years are shown in Table 3 . Patients with IHMB had significantly higher 3-year rates of mortality (24.6% vs. 5.4%, p Ͻ 0.0001) ( Fig. 2A) and MACE (40.3% vs. 20.5%, p Ͻ 0.0001) (Fig. 2B) . Moreover, the rates of mortality and MACE were significantly higher in patients with IHMB within each time interval (Fig. 3) . The 3-year cumulative rates of MI, ischemic target vessel revascularization, and stroke were also significantly higher in patients with IHMB. Rates of stroke were significantly higher in the bleeding group within 30 days and between 30 days to 1 year, but not thereafter (Table 3 ). The 3-year cumulative rates of ST were not significantly increased in patients with compared to those without IHMB.
IHMB was still associated with 3-year mortality (Online Fig. A) and MACE (Online Fig. B) after exclusion of patients with large hematomas alone (n ϭ 13). Predictors of long-term mortality. IHMB was an independent predictor of 3-year mortality (hazard ratio [HR]: 2.80, 95% confidence interval [CI]: 1.89 to 4.16; p Ͻ 0.0001). Other independent predictors included in-hospital ST, age, male sex, diabetes mellitus, renal insufficiency, smoking, Killip classes 2 to 4 at admission, anemia, baseline white blood cell count, left anterior descending artery culprit lesion, and final Thrombolysis In Myocardial Infarction flow grade Ͻ3 (Table 4) .
In the secondary analysis among in-hospital survivors (n ϭ 3,260), IHMB remained an independent predictor of 3-year mortality (HR: 2.26, 95% CI: 1.43 to 3.54; p ϭ 0.0004), while in-hospital ST was not a significant predictor (HR: 0.95; 95% CI: 0.13 to 6.93).
Discussion
In the present analysis from the HORIZONS-AMI trial, we found that the occurrence of IHMB in ST-segment elevation myocardial infarction patients treated with primary PCI confers a sustained risk of both mortality and MACE for at least 3 years. We also identified several important differences in pharmacotherapy at the time of discharge between patients with and without IHMB that may in part explain the effect on late mortality.
Although the incidence of both mortality and MACE among bleeding patients was greatest in the first 30 days following PCI, the risk of late mortality after IHMB continued to monotonically accrue over time. While the deleterious impact of thrombotic complications is principally evidenced in the acute stage after their occurrence (6), our findings do not suggest a similar attenuation of risk over time in patients with IHMB in the setting of STEMI. Indeed, IHMB was associated with an approximate 3.5-fold increased risk of mortality between 1 and 3 years. In this study, IHMB was adjudicated according to the protocol definition used in the HORIZONS-AMI and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trials (3, 7) . This report, therefore, validates the definition of major bleeding used in these studies as being clinically relevant and useful in predicting long-term prognosis.
The incidence of IHMB in the present study is higher than that reported from earlier analyses in other acute coronary syndrome studies (1, 8) . Differences in patient populations, treatment strategies, and bleeding definitions likely explain these discrepancies. Using the same protocol definition, the rate of IHMB among acute coronary syndrome patients treated with PCI in the ACUITY trial was 5.9% (9) .
IHMB was associated with 3-year mortality and MACE after the exclusion of patients with large hematomas alone, and the influence of single large hematoma on subsequent mortality or MACE seems to be negligible, as in previous reports (10, 11) .
Bleeding complications after acute MI may have detrimental effects on long-term prognosis due to several reasons. Patients with IHMB were discharged less often on beta-blocker and 
